Clinical features of acute esophageal mucosal lesions and reflux esophagitis Los Angeles classification grade D: A retrospective study

Table 1 Patient background and medications, n (%)

Parameter	AEML (n = 105)		RE-D (n = 48)	Risk ratio (95%CI)	P value
	Black esophagus (n = 19)	Non-black esophagus (n = 86)
Age in yr, median (IQR)	75.0 (65.0–85.0)		87.0 (78.0–91.3)	0.34	< 0.001
	83.0 (71.5–86.0)	75.0 (65.0–84.0)
Male	61 (58.1)		13 (27.1)	2.15 (1.31–3.51)	< 0.001
	11 (57.9)	50 (58.1)
Chief complaint					0.713
Hematemesis	30 (28.3)		16 (33.3)
	6 (31.6)	24 (27.9)
Black vomiting	65 (61.0)		26 (54.2)
	10 (52.6)	54 (62.8)
Black stools	11 (10.5)		6 (12.5)
	3 (15.8)	8 (9.3)
Presence of shock vitality	29 (27.6)		8 (16.7)	1.66 (0.82–3.35)	0.16
	6 (31.6)	23 (26.7)
Underlying conditions
Hypertension	49 (46.7)		23 (47.9)	0.97 (0.68–1.39)	1
	13 (68.4)	36 (41.9)
Diabetes mellitus	23 (22.1)		4 (8.3)	2.63 (0.96–7.18)	0.043
	4 (21.1)	19 (22.4)
Chronic kidney disease	19 (18.3)		7 (14.6)	1.24 (0.56–2.75)	0.649
	5 (26.3)	14 (16.5)
Coronary artery disease	13 (12.4)		1 (2.1)	5.94 (0.8–44.14)	0.065
	3 (15.8)	10 (11.6)
Liver cirrhosis	3 (2.9)		2 (4.2)	0.69 (0.12–3.97)	0.649
	0 (0.0)	3 (3.5)
Previous malignancy	30 (28.6)		5 (10.4)	2.74 (1.13–6.63)	0.013
	7 (36.8)	23 (26.7)
Medications
NSAIDs	13 (12.4)		2 (4.2)	2.97 (0.70–12.66)	0.148
	3 (15.8)	10 (11.6)
Antithrombotic	28 (26.7)		17 (35.4)	0.75 (0.46–1.24)	0.339
	3 (15.8)	25 (29.1)
Steroids	4 (3.8)		1 (2.1)	1.83 (0.21–15.93)	1
	0 (0.0)	4 (4.7)
Antibiotics	8 (7.6)		1 (2.1)	3.66 (0.47–28.4)	0.274
	2 (10.5)	6 (7.0)
Acid blockers	42 (40.4)		15 (31.2)	1.28 (0.79–2.07)	0.368
	10 (52.6)	32 (37.6)

Age was calculated with an effect size r because the risk ratio could not be calculated. 95%CI: 95% confidence interval; AEML: Acute esophageal mucosal lesion; IQR: Interquartile range; NSAIDs: Nonsteroidal anti-inflammatory drugs; RE-D: Reflux esophagitis Los Angeles classification grade D.